. . . . "T,790,M" . . . . . . . . . . . . . . . . . "a(CHEBI:gefitinib) =| kin(p(HGNC:EGFR))" . "p(HGNC:EGFR,sub(T,790,M)) =| (a(CHEBI:gefitinib) =| kin(p(HGNC:EGFR)))" . "Approximately 61,000 statements." . "Copyright (c) 2011-2012, Selventa. All rights reserved." . "BEL Framework Large Corpus Document" . . "20131211" . "show a good clinical response to EGFR TKIs such as gefitinib, but they almost invariably develop drug resistance after an average of 12 months5. A secondary mutation in exon 20 (T790M) is found in about half of patients with a primary mutation that have grown resistant after an initial response to EGFR TKIs6–8. More recently, a new secondary mutation (D761Y) was found in a brain metastasis of a lung cancer initially responsive to gefitinib9. So far, T790M and D761Y are the only acquired alterations identified in the EGFR associated with escape from TKI therapy." . . "Selventa" . . . . "2014-07-03T14:33:10.890+02:00"^^ . . .